Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | PHGDH | O43175 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21224324 | 1.00 | SCD (0.57) | SCDALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL21225185 | 0.95 | SCD (0.54) | SCDALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL21225186 | 0.95 | SCD (0.54) | SCDALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL21224221 | 0.94 | SMN1; SMN2 (0.53) | SCDALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL21241955 | 0.94 | SCD (0.53) | SCDALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL22971536 | 0.94 | SCD (0.53) | SCDALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL21225227 | 0.94 | SCD (0.53) | SCDALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL21224219 | 0.94 | SMN1; SMN2 (0.53) | SCDALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL21225226 | 0.94 | SCD (0.53) | SCDALDH1A1MEN1CRHBPKMT2A | |
| SCHEMBL21224713 | 0.93 | SCD (0.52) | SCDALDH1A1MEN1CRHBPKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383560-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-11497752-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2021-02-11 | — | — | US | disclosed |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2021-02-11 | — | — | US | disclosed |
| CN-112153984-A | Compound and use thereof | 福宏治疗公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-3746124-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019152437-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152437-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | SCD 3594/4885ALDH1A1 2571/4885MEN1 1366/4885 |
| US-12383560-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | SCD 3594/4885ALDH1A1 2571/4885MEN1 1366/4885 |
| US-11497752-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | SCD 3594/4885ALDH1A1 2571/4885MEN1 1366/4885 |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | SCD 3594/4885ALDH1A1 2571/4885MEN1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.